WELCOME TO
BSG LIVE’25

Starting with what you’d want from an advanced therapy and then an overview of filgotinib’s phase III trials, including safety and cs-free data. This will segway into the recently published 5-year long term efficacy and safety data for filgotinib. The symposium will finish on JAKi switching data and summarise the points made initially.

Speaker:

• Dr Kamal Patel
• St George’s University Hospitals NHS FT